Minerva Neurosciences, Inc.

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of product candidates aimed at treating central nervous system (CNS) diseases. Headquartered in Burlington, Massachusetts, USA, the company's mission is to improve the lives of patients by providing enhanced therapeutic options for conditions with significant unmet medical needs.

The company's pipeline focuses on several CNS disorders, with its lead product candidate being roluperidone (MIN-101). This compound is currently in a Phase 3 confirmatory trial for the treatment of negative symptoms in patients diagnosed with schizophrenia. Minerva Neurosciences is also developing MIN-301 for Parkinson's disease. Additionally, it co-developed seltorexant (MIN-202) with Janssen Pharmaceutica NV for insomnia disorder and adjunctive treatment of Major Depressive Disorder, with Janssen progressing seltorexant through Phase 3 trials.

Minerva Neurosciences is publicly traded on NASDAQ under the ticker symbol NERV. In April 2026, the company announced a leadership transition, with Jim O'Connor appointed as Chief Business Officer and General Counsel. Earlier in March 2026, Minerva initiated patient screening for its global Phase 3 confirmatory trial of roluperidone for schizophrenia. The company secured financing of up to $200 million in October 2025 to support the advancement of roluperidone through its Phase 3 trial and prepare for a New Drug Application resubmission.